Clinical and treatment outcomes, prognostic factors, and survival in pediatric acute leukemia
Abstract
Purpose: The aim of this study was to evaluate overall survival and treatment-related mortality in children with acute leukemia treated in a middle-income healthcare setting and to test the hypothesis that early treatment response and sex independently predict survival outcomes. Materials and Methods: We retrospectively analyzed 105 pediatric patients diagnosed with acute leukemia between February 2021 and May 2023 at the Health Sciences University, Adana City Training and Research Hospital, Turkey. Data were obtained from institutional electronic medical records. Overall and event-free survival were estimated using the Kaplan–Meier method and compared using the log-rank test. Results: The median age was 9 years. Acute lymphoblastic leukemia was diagnosed in 91 patients, acute myeloid leukemia in 13, and mixed-phenotype acute leukemia in one. The overall survival rate was 62.6%. Survival was higher in girls than in boys (80% vs. 48%). Patients with a favorable day-8 steroid response demonstrated substantially higher survival than poor responders (83% vs. 35%). In multivariate analysis, early steroid response was independently associated with a marked reduction in mortality risk. Conclusion: In this single-center cohort from a middle-income country, female sex and early steroid response were associated with improved survival in pediatric acute leukemia. However, treatment-related mortality remained substantial, underscoring the need to strengthen supportive care, infection control, and access to modern risk-stratified monitoring. Incorporation of early response assessment and molecular follow-up into routine clinical practice may further improve outcomes, although the lack of minimal residual disease data limited more refined prognostic stratification.
Keywords
acute leukemia , children , treatment outcomes , pediatric hematology , clinical findings
Kaynakça
- Fish JD, Lipton JM, Lanzkowsky P. Lanzkowsky’s Manual of Pediatric Hematology and Oncology. 6th ed. New York, Academic Press, 2021.
- Pizzo PA, Poplack DG. Principles and Practice of Pediatric Oncology. 7th ed. Philadelphia, Lippincott Williams & Wilkins, 2015.
- Bhojwani D, Yang JJ, Pui CH. Biology of childhood acute lymphoblastic leukemia. Pediatr Clin North Am. 2015;62:47–60.
- De Oliveira BM, Viana MB, Zani CL, Romanha AJ. Clinical and laboratory evaluation of compliance in acute lymphoblastic leukaemia. Arch Dis Child. 2004;89:785–8.
- Ferrando AA, Lopez-Otin C. Clonal evolution in leukemia. Nat Med. 2017;23:1135–45.
- Ganzel C, Rowe JM. Prognostic factors in adult acute leukemia. Hematol Oncol Clin North Am. 2011;25:1163–87.
- Hazar V, Karasu GT, Uygun V, Akcan M, Küpesiz A, Yeşilipek A et al. Childhood acute lymphoblastic leukemia in Turkey: factors influencing treatment and outcome, a single center experience. J Pediatr Hematol Oncol. 2010;32:e317–22.
- De Jong D, Haferlach T. Haematolymphoid malignancies: beyond the current classifications. Histopathology. 2024;86:1–15.
- Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Schrappe M et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group. Leukemia. 2010;24:265–84.
- Maloney KW, Devidas M, Wang C, Carroll WL, Winick N, Hunger SP et al. COG Update 2023: precision therapy in pediatric acute leukemia. J Clin Oncol. 2023;41:2112–28.
